The estimated Net Worth of Peter C Farrell is at least $81.8 Million dollars as of 4 September 2024. Peter Farrell owns over 2,000 units of Resmed stock worth over $22,055,636 and over the last 21 years he sold RMD stock worth over $59,058,327. In addition, he makes $681,849 as Non-Executive Chairman of the Board at Resmed.
Peter has made over 251 trades of the Resmed stock since 2003, according to the Form 4 filled with the SEC. Most recently he sold 2,000 units of RMD stock worth $479,800 on 4 September 2024.
The largest trade he's ever made was exercising 400,000 units of Resmed stock on 30 January 2013 worth over $9,240,000. On average, Peter trades about 11,009 units every 21 days since 2003. As of 4 September 2024 he still owns at least 87,204 units of Resmed stock.
You can see the complete history of Peter Farrell stock trades at the bottom of the page.
Dr. Peter C. Farrell Ph.D. serves as Non-Executive Chairman of the Board of the Company. Dr. Farrell served as vice president of research and development at various subsidiaries of Baxter International, Inc. He served on the Visiting Committee of the Harvard/Massachusetts Institute of Technology Health Sciences & Technology Program from 1998 through 2018 and currently serves on the MIT Dean of Engineering’s Advisory Council. Dr. Farrell also serves as independent board chair at Arcturus Therapeutics Ltd (NASDAQ: ARCT), a self-replicating RNA therapeutics company, and on two faculty advisory boards at the University of California, San Diego: the Rady Business School and the Jacobs Engineering School. He is also chair of WaveGuide, a startup leveraging nuclear magnetic resonance technology developed within Harvard’s School of Physics. Dr. Farrell is a fellow or honorary fellow of several professional bodies. In 2012, he became an elected member of the US National Academy of Engineering and joined the board of trustees of Scripps Research. He was named 2005 U.S. National Entrepreneur of the Year for Health Sciences, 2001 Australian Entrepreneur of the Year, and 1998 San Diego Entrepreneur of the Year for Health Sciences. He has served on the Executive Council of the Division of Sleep Medicine at Harvard Medical School since 1998, served as vice-chair from 2000 until 2010, and chair until May 2013. He was awarded the Chancellor’s Medal from UCSD in 2016 and received the Gordon Fellow Award from UCSD in 2012.
As the Non-Executive Chairman of the Board of Resmed, the total compensation of Peter Farrell at Resmed is $681,849. There are 11 executives at Resmed getting paid more, with Michael Farrell having the highest compensation of $10,429,800.
Peter Farrell is 78, he's been the Non-Executive Chairman of the Board of Resmed since 2014. There are 1 older and 20 younger executives at Resmed. The oldest executive at Resmed Inc. is Dr. Peter C. Farrell A.M., AM, B.E., BE (Hons), Ph.D., ScD, 79, who is the Founder & Non-Exec. Chairman.
Over the last 23 years, insiders at Resmed have traded over $250,830,262 worth of Resmed stock and bought 10,000 units worth $424,500 . The most active insiders traders include Peter C Farrell, Gary W Pace, and David Pendarvis. On average, Resmed executives and independent directors trade stock every 7 days with the average trade being worth of $3,005,701. The most recent stock trade was executed by Brett Sandercock on 9 September 2024, trading 1,000 units of RMD stock currently worth $246,420.
at resmed (nyse: rmd, asx: rmd) we pioneer innovative solutions that treat and keep people out of the hospital, empowering them to live healthier, higher-quality lives. our cloud-connected medical devices transform care for people with sleep apnea, copd and other chronic diseases. our comprehensive out-of-hospital software platforms support the professionals and caregivers who help people stay healthy in the home or care setting of their choice. by enabling better care, we improve quality of life, reduce the impact of chronic disease and lower costs for consumers and healthcare systems in more than 120 countries.
Resmed executives and other stock owners filed with the SEC include: